[Fenoldopam: potential clinical applications in heart surgery].
Fenoldopam mesylate, a derivative of benzazepine, is the first selective agonist of dopamine-1 (DA1) receptors authorized for clinical use. Fenoldopam mesylate causes relaxation of smooth muscle, vasodilatation and inhibition of tubular reabsorption of sodium in the kidney. Fenoldopam has no dopamine-2, alpha or beta-adrenergic activity and is 3.5 times more potent than dopamine in dilating renal vessels. Fenoldopam mesylate may therefore prove useful in situations in which renal oxygen demand must be reduced and supply increased. Intravenous fenoldopam mesylate significantly increased renal blood flow and decreased vascular resistance in healthy volunteers and hypertensive patients.
Shorten
G D
GD
Department of Anaesthesia and Intensive Care Medicine, University College, Cork, Irlanda.
D058186:Acute Kidney Injury / Q000517:prevention & control; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005112:Extracorporeal Circulation / Q000009:adverse effects; D018818:Fenoldopam / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007431:Intraoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D007511:Ischemia / Q000517:prevention & control; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology; D007683:Kidney Tubular Necrosis, Acute / Q000517:prevention & control; D008643:Mesentery / Q000098:blood supply; D017202:Myocardial Ischemia / Q000150:complications / Q000601:surgery; D009318:Natriuresis / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D017447:Receptors, Dopamine D1 / Q000819:agonists* / Q000502:physiology; D012077:Renal Artery / Q000187:drug effects; D012079:Renal Circulation / Q000187:drug effects*; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D004232:Diuretics; D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D014665:Vasodilator Agents; D018818:Fenoldopam